Glycosmedia Weekly Diabetes News Update
View this email in your browser

Gold Sponsors:

Novo Nordisk

AstraZeneca

Boehringer Ingelheim

Silver Sponsors:

Abbott Diabetes Care

Ascensia Diabetes Care

Ericas

Glycosmedia Weekly Diabetes News - 04/22/2022

Correlation between the accumulation of skin glycosylation end products and the development of type 2 diabetic peripheral neuropathy

The cumulative amount of skin AGEs can be used as the diagnostic index and the prediction and evaluation index of DPN severity. Moreover, the diabetic peripheral neuropathy risk score can predict the risk of DPN in patients with T2DM (BMC Endocrine Disorders)


Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes

These findings can be used by clinicians to motivate patients in achieving the recommended treatment goals and to help prioritize interventions and programs to improve diabetes care in the US (JAMA)


Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension

One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss, with similar changes in cardiometabolic parameters (Diabetes, Obesity and Metabolism)


Keeping It Local in Metabolic Disease: Adipose Tissue Paracrine Signaling and Insulin Resistance

This article highlights the important role of adipose tissue paracrine signaling on metabolic function and insulin sensitivity in nearby tissues and organs, specifically focusing on visceral, pancreatic, subcutaneous, intermuscular, and perivascular adipose tissue depots (Diabetes)


Type 2 diabetes classification: a data-driven cluster study of the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort

Different HOMA2-based approaches did not classify patients with T2D in a consistent manner. The T2D classes characterized by high insulin resistance/hyperinsulinemia appeared most distinct (BMJ Open, Diabetes Research & Care)


Cardiovascular and renal outcomes of initial combination therapy with glucose-lowering agents versus stepwise approach in newly diagnosed or treatment naïve type 2 diabetes: a systematic review and meta-analysis

Except for improving cardiometabolic and glycaemic parameters, a limited number of studies characterised by small sample sizes show that initial combination therapy for newly diagnosed T2D may be similar in efficacy and safety to stepwise therapy with respect to cardio-renal outcomes. There is a lack of sufficient evidence to recommend initial combination therapy with glucose-lowering agents in newly diagnosed T2D with the aim of preventing cardio-renal outcomes. Definitive RCTs are warranted (Diabetes, Obesity and Metabolism)


Share
Tweet
Forward
+1
Share
Please visit the Glycosmedia website for more features and information, including:

Journal Watch
Comment on recently published papers written by the medical editors of Glycosmedia.

Diabetes Updates
Updates written by Professor Steve Bain (Diabetologist) and Dr. Mark Freeman (Diabetologist).

Book and Product Reviews
A selection of book and product reviews written by the contributing editors of Glycosmedia.
The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Glycosmedia complies with the HONcode standard for trustworthy health information: verify here.


Copyright © 2022 Glycosmedia Partnership

Our mailing address is:
Glycosmedia
9 Woodburn Drive
West Cross
Swansea, West Glamorgan SA3 5TZ
United Kingdom

Add us to your address book


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp